Lawrence F. Eichenfield, MD, Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital-San Diego, discusses the recent U.S. Food and Drug Administration (FDA) nod for roflumilast cream 0.05% (Zoryve, Arcutis) in kids aged 2 to 5 with atopic dermatitis (AD) and how it will affect clinical practice.
